Financial News
All
Basic Materials
Communication Services
Consumer Cyclical
Consumer Defensive
Energy
Financial Services
Healthcare
Industrials
Real Estate
Technology
Utilities
Macro
All Sentiment
Bullish
Neutral
Bearish
2,045 articles
Rhythm Pharma Wins FDA Approval For First-Ever Rare Weight Disorder Therapy
The U.S. Food and Drug Administration (FDA) on Thursday approved an expanded indication for Rhythm Pharmaceuticals Inc.’s...
📰
Should Value Investors Buy Catalyst Pharmaceuticals (CPRX) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks....
📰
Here's Why Integer (ITGR) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Glaukos Launches Epioxa, Boosts Growth in Corneal Treatments
GKOS launches Epioxa, the first FDA-approved topical keratoconus therapy, targeting an underserved market and positioning the company for long-term...
Glaukos Launches Epioxa, Boosts Growth in Corneal Treatments
GKOS launches Epioxa, the first FDA-approved topical keratoconus therapy, targeting an underserved market and positioning the company for long-term...
Glaukos Launches Epioxa, Boosts Growth in Corneal Treatments
GKOS launches Epioxa, the first FDA-approved topical keratoconus therapy, targeting an underserved market and positioning the company for long-term...
Glaukos Launches Epioxa, Boosts Growth in Corneal Treatments
GKOS launches Epioxa, the first FDA-approved topical keratoconus therapy, targeting an underserved market and positioning the company for long-term...
📰
CIMG Inc. Announces Liquidity Provider Agreement with The Ching Labs to Support DeSyn Pool TVL
HONG KONG, March 20, 2026 /PRNewswire/ -- CIMG Inc. ("CIMG" or the "Company") (Nasdaq: CIMG), a business group specializing in digital health and...
Google Brings Gemini To Mac In Early Test To Rival ChatGPT
Alphabet Inc.’s (NASDAQ:GOOGL) (NASDAQ:GOOG) Google is stepping up its AI push with a dedicated Gemini app for Apple Inc.’s (NASDAQ:AAPL)...
📰
Protagonist Therapeutics (PTGX) Soars 4.7%: Is Further Upside Left in the Stock?
Protagonist Therapeutics (PTGX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings...
📰
Protagonist Therapeutics (PTGX) Soars 4.7%: Is Further Upside Left in the Stock?
Protagonist Therapeutics (PTGX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings...
This Rubrik Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Friday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades...
This Rubrik Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Friday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades...
This Rubrik Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Friday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades...
The Gold Mine That Barrick Bought Into, a Billionaire Backed, and the Market Still Hasn't Found
LVG, KGC, FNV, WPM, and EQX as the Gold Supercycle Enters Its Most Profitable Phase Issued on behalf of Lake Victoria Gold Ltd. Companies mentioned...
FNB Selected as Penn State's Official Provider of Retail Banking and Financial Services
UNIVERSITY PARK, Pa., March 20, 2026 /PRNewswire/ -- F.N.B. Corporation (NYSE: FNB) today announced a partnership with Penn State that establishes...
BTS Comeback Becomes Netflix's Biggest Live Bet Yet
Netflix Inc. (NASDAQ:NFLX) is expanding its growth strategy across content, live experiences, and internal restructuring to strengthen its long-term...
Amazon Eyes Smartphone Comeback — 'Transformer' Project Reportedly Targets AI-Driven Future
Amazon.com Inc (NASDAQ:AMZN) is dialing up a second attempt at the smartphone market. More than a decade after the Fire Phone was scrapped, the...
FDA Approves Novo Nordisk's Higher-Dose Wegovy for Obesity Patients
NVO wins FDA's accelerated nod for a higher 7.2 mg Wegovy dose, backed by strong phase III weight-loss data, with a U.S. launch planned for April...
FDA Approves Novo Nordisk's Higher-Dose Wegovy for Obesity Patients
NVO wins FDA's accelerated nod for a higher 7.2 mg Wegovy dose, backed by strong phase III weight-loss data, with a U.S. launch planned for April...
FDA Approves Novo Nordisk's Higher-Dose Wegovy for Obesity Patients
NVO wins FDA's accelerated nod for a higher 7.2 mg Wegovy dose, backed by strong phase III weight-loss data, with a U.S. launch planned for April...
FDA Approves Novo Nordisk's Higher-Dose Wegovy for Obesity Patients
NVO wins FDA's accelerated nod for a higher 7.2 mg Wegovy dose, backed by strong phase III weight-loss data, with a U.S. launch planned for April...
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers
Azitra (AMEX:AZTR) stock moved upwards by 87.3% to $0.33 during Friday's pre-market session. The company's market cap stands at...
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers
Azitra (AMEX:AZTR) stock moved upwards by 87.3% to $0.33 during Friday's pre-market session. The company's market cap stands at...
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers
Azitra (AMEX:AZTR) stock moved upwards by 87.3% to $0.33 during Friday's pre-market session. The company's market cap stands at...
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers
Azitra (AMEX:AZTR) stock moved upwards by 87.3% to $0.33 during Friday's pre-market session. The company's market cap stands at...
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers
Azitra (AMEX:AZTR) stock moved upwards by 87.3% to $0.33 during Friday's pre-market session. The company's market cap stands at...
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers
Azitra (AMEX:AZTR) stock moved upwards by 87.3% to $0.33 during Friday's pre-market session. The company's market cap stands at...
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers
Azitra (AMEX:AZTR) stock moved upwards by 87.3% to $0.33 during Friday's pre-market session. The company's market cap stands at...
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers
Azitra (AMEX:AZTR) stock moved upwards by 87.3% to $0.33 during Friday's pre-market session. The company's market cap stands at...
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers
Azitra (AMEX:AZTR) stock moved upwards by 87.3% to $0.33 during Friday's pre-market session. The company's market cap stands at...
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers
Azitra (AMEX:AZTR) stock moved upwards by 87.3% to $0.33 during Friday's pre-market session. The company's market cap stands at...
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers
Azitra (AMEX:AZTR) stock moved upwards by 87.3% to $0.33 during Friday's pre-market session. The company's market cap stands at...
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers
Azitra (AMEX:AZTR) stock moved upwards by 87.3% to $0.33 during Friday's pre-market session. The company's market cap stands at...
Anavex Life Lead Drug Targets Early Alzheimer's Cause - New Study Highlights
Anavex Life Sciences Corp. (NASDAQ:AVXL) on Friday announced that a new peer-reviewed study published by the University of California in Proceedings...
📰
OCGN Gene-Agnostic Eye Therapy Could Shift Retinal Drug Development
OCGN's gene-agnostic eye therapy aims to treat multiple retinal mutations, with key filings and pivotal data in 2026???2027 set to test its broad...
📰
OCGN Gene-Agnostic Eye Therapy Could Shift Retinal Drug Development
OCGN's gene-agnostic eye therapy aims to treat multiple retinal mutations, with key filings and pivotal data in 2026???2027 set to test its broad...
📰
OCGN Gene-Agnostic Eye Therapy Could Shift Retinal Drug Development
OCGN's gene-agnostic eye therapy aims to treat multiple retinal mutations, with key filings and pivotal data in 2026???2027 set to test its broad...
OCGN Gene Therapy Pipeline: 2026-2027 Catalysts To Watch
Ocugen lines up key gene therapy catalysts through 2027, with pivotal data, filings, and milestones across three eye programs set to drive stock...
OCGN Gene Therapy Pipeline: 2026-2027 Catalysts To Watch
Ocugen lines up key gene therapy catalysts through 2027, with pivotal data, filings, and milestones across three eye programs set to drive stock...
OCGN Gene Therapy Pipeline: 2026-2027 Catalysts To Watch
Ocugen lines up key gene therapy catalysts through 2027, with pivotal data, filings, and milestones across three eye programs set to drive stock...
UnitedHealth Group Incorporated $UNH Shares Bought by Davis Selected Advisers
Davis Selected Advisers grew its stake in shares of UnitedHealth Group Incorporated (NYSE:UNH – Free Report) by 0.6% in the third quarter,...
UnitedHealth Group Incorporated $UNH Shares Bought by Davis Selected Advisers
Davis Selected Advisers grew its stake in shares of UnitedHealth Group Incorporated (NYSE:UNH – Free Report) by 0.6% in the third quarter,...
UnitedHealth Group Incorporated $UNH Shares Bought by Davis Selected Advisers
Davis Selected Advisers grew its stake in shares of UnitedHealth Group Incorporated (NYSE:UNH – Free Report) by 0.6% in the third quarter,...
Prestige Bets $1 Billion On World's Most Iconic Nasal Strip
Prestige Consumer Healthcare Inc. (NYSE:PBH) on Friday announced a definitive agreement to acquire the Breathe Right brand for $1.045 billion.
The...
EXCLUSIVE: Co-Diagnostics Expands South Asia Reach, Targets $13 Billion Market Opportunity
Co-Diagnostics Inc. (NASDAQ:CODX) on Friday signed an agreement for CoSara Diagnostics Pvt. Ltd, to expand its commercial and distribution territory...
Here's Why You Should Add McKesson Stock to Your Portfolio Now
McKesson's strong oncology, GLP-1, and biopharma growth fuel earnings momentum, but margin pressure and segment volatility remain key watch points.
Here's Why You Should Add McKesson Stock to Your Portfolio Now
McKesson's strong oncology, GLP-1, and biopharma growth fuel earnings momentum, but margin pressure and segment volatility remain key watch points.